Lasmiditan: First Approval
- 115 Downloads
Lasmiditan (REYVOW™; Eli Lilly and Company) is an orally available serotonin (5-HT)1F receptor agonist. In October 2019, the US FDA approved lasmiditan 50 mg and 100 mg tablets for the acute treatment of migraine with or without aura in adults. Approval was based on positive results from two pivotal phase III trials, in which lasmiditan significantly improved the proportions of patients achieving freedom from headache pain and freedom from the most bothersome symptom (photophobia, phonophobia or nausea), relative to placebo, when used to treat a migraine with moderate to severe pain. Lasmiditan is not for use in the preventive treatment of migraine. This article summarizes the milestones in the development of lasmiditan leading to its first approval for the acute treatment of migraine in adults.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflict of Interest
During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Yvette Lamb is a salaried employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.
- 1.Eli Lilly. REYVOW (lasmiditan) tablets, for oral use [controlled substance schedule pending]: US prescribing information. 2019. http://pi.lilly.com/. Accessed 11 Nov 2019.
- 2.US Food & Drug Administration (FDA). FDA approves new treatment for patients with migraine [media release]. 11 Oct 2019. http://www.fda.gov.
- 5.Eli Lilly. Lilly’s REYVOW™ (lasmiditan), the first and only medicine in a new class of acute treatment for migraine, receives FDA approval [media release]. 11 Oct 2019. http://www.prnewswire.com.
- 6.Eli Lilly. Lilly completes acquisition of CoLucid Pharmaceuticals [media release]. 01 Mar 2017. http://www.lilly.com.
- 7.United States Securities and Exchange Commission. Schedule 14D-9 form: solicitation/recommendation statement (CoLucid Pharmaceuticals, Inc.). 2017. http://www.sec.gov/. Accessed 11 Nov 2019.
- 8.CoLucid Pharmaceuticals, Ildong Pharmaceutical Co Ltd. CoLucid Pharmaceuticals and ILDONG Pharmaceutical enter into a distribution and supply agreement for lasmiditan, a novel agent for acute migraine [media release]. 22 Oct 2013. http://www.colucid.com.
- 11.Pearlman EM, Doty EG, Dennehy EB, et al. Effects of lasmiditan on driving performance: results of 2 randomized, blinded, crossover simulated driving studies with placebo and active controls (abstract no. IOR06). Headache. 2019;59(Suppl 1):22–3.Google Scholar
- 13.Wilbraham D, Tsai M, Case MG. Effects of lasmiditan on cardiovascular parameters in healthy subjects receiving oral doses of propranolol [abstract no. P114]. Headache. 2019;59(Suppl 1):99.Google Scholar
- 14.Berg PH, Wilbraham D, Tsai M. Effects of lasmiditan when coadministered with sumatriptan: results of a randomized, double-blind, crossover study in healthy subjects [abstract no. 145]. Headache. 2019;59(Suppl 1):115.Google Scholar
- 15.Berg PH, Wilbraham D, Tsai M. Effects of lasmiditan when coadministered with topiramate: results of a parallel, placebo-controlled, fixed-sequence study in healthy subjects [abstract no. P146]. Headache. 2019;59(Suppl 1):116.Google Scholar
- 18.Ashina M, Vasudeva R, Jin L, et al. Onset of efficacy following oral treatment with lasmiditan for the acute treatment of migraine: integrated results from two randomized double-blind placebo-controlled phase 3 clinical studies. Headache. 2019. https://doi.org/10.1111/head.13636.CrossRefPubMedGoogle Scholar
- 21.Shapiro RE, Hochstetler HM, Dennehy EB, et al. Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials. J Headache Pain. 2019;20(90):1–10.Google Scholar